Benicar reverses narrowing of arteries
A study funded by Japanese pharmaceutical company Daiichi Sankyo Inc. showed that their product Benicar (sold as Olmetec in Europe) helps reverse the narrowing of arteries in patients with high blood pressure.
The study was conducted in the USA at the Wake Forest University Baptist Medical Center and the results published in the Journal of the American Society of Hypertension. The study concluded that after a year of treatment using Benicar (chemical name olmesartan medoxomil), patients with high blood pressure saw improvements in artery abnormalities and also found that arterial architecture were returned to normal levels, as opposed to no change in patients treated with atenolol.
Benicar belongs to a class of anti-hypertensive medications that block the angiotensin II receptor on the blood vessels that causes constriction and increase blood pressure. It also blocks the release of a hormone that causes salt retention and increased blood volume.
